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Mills DE, Johnson MA, McPhilimey MJ, Williams NC, Gon-
zalez JT, Barnett YA, Sharpe GR. The effects of inspiratory mus-
cle training on plasma interleukin-6 concentration during cycling
exercise and a volitional mimic of the exercise hyperpnea. J
Appl Physiol 115: 1163–1172, 2013. First published July 25, 2013;
doi:10.1152/japplphysiol.00272.2013.—It is unknown whether the
respiratory muscles contribute to exercise-induced increases in plasma
interleukin-6 (IL-6) concentration, if this is related to diaphragm
fatigue, and whether inspiratory muscle training (IMT) attenuates the
plasma IL-6 response to whole body exercise and/or a volitional
mimic of the exercise hyperpnea. Twelve healthy males were divided
equally into an IMT or placebo (PLA) group, and before and after a
6-wk intervention they undertook, on separate days, 1 h of 1) passive
rest, 2) cycling exercise at estimated maximal lactate steady state
power (EX), and 3) volitional hyperpnea at rest, which mimicked the
breathing and respiratory muscle recruitment patterns achieved during
EX (HYPEX). Plasma IL-6 concentration remained unchanged during
passive rest. The plasma IL-6 response to EX was reduced following
IMT (main effect of intervention, P  0.039) but not PLA (P 
0.272). Plasma IL-6 concentration increased during HYPEX (main
effect of time, P  0.01) and was unchanged postintervention. There
was no evidence of diaphragm fatigue (measured by phrenic nerve
stimulation) following each trial. In conclusion, plasma IL-6 concen-
tration is increased during EX and HYPEX and this occurred in the
absence of diaphragm fatigue. Furthermore, IMT reduced the plasma
IL-6 response to EX but not HYPEX. These findings suggest that the
respiratory muscles contribute to exercise-induced increases in plasma
IL-6 concentration in the absence of diaphragm fatigue and that IMT
can reduce the magnitude of the response to exercise but not a
volitional mimic of the exercise hyperpnea.
interleukin-6; exercise; respiratory muscles; diaphragm fatigue; in-
spiratory muscle training
INCREASED RESPIRATORY MUSCLE work is encountered during
strenuous whole body exercise, asthma attacks, and exacerba-
tions of chronic obstructive pulmonary disease (COPD) and
when sufficiently strenuous can result in diaphragmatic fatigue.
These scenarios can result in systemic inflammation and oxi-
dative stress due to enhanced production of inflammatory
cytokines and reactive oxygen species (ROS), respectively (35,
50, 68).
During whole body exercise the myokine interleukin-6
(IL-6) demonstrates the largest increase (50), with contracting
skeletal muscle accounting for most (but not all) of the exer-
cise-induced increase in plasma IL-6 concentration (58). IL-6
acts to stimulate lipolysis (67), hepatic glucose output (20), and
glucose uptake in the contracting myocytes (10). However, not
all skeletal muscles release the same amount of IL-6 during
whole body exercise. When expressed relative to the size of the
muscle group used, the arm muscles release greater amounts of
IL-6 than leg muscles, which may be due to differences in
fiber-type composition and vascular supply (26).
The respiratory muscles also exhibit different fiber-type
composition and vascular supply compared with leg muscles
(48), but given their relatively small mass [960 g (23)] it may
seem unlikely that they contribute to exercise-induced in-
creases in plasma IL-6 concentration. However, Vassilakopou-
los et al. (64) reported a 120% increase in plasma IL-6
concentration in young and healthy humans following inspira-
tory resistive loading (IRL) at 75% maximal inspiratory mouth
pressure (MIP). The increase in plasma IL-6 concentration was
attributed to increased rates of IL-6 release from the inspiratory
muscles, which is supported by the observation of increased
IL-6 mRNA and protein expression in the diaphragm of rats
exposed to IRL (53, 54, 62). Although these findings have
clinical relevance to those with asthma and obstructive lung
disease, they cannot be generalized to healthy humans per-
forming whole body exercise as, compared with IRL, sponta-
neous exercise hyperpnea elicits different breathing and respi-
ratory muscle recruitment patterns (14, 15, 18).
Vassilakopoulos et al. (63, 64) also suggested that the
increase in plasma IL-6 concentration (and other cytokines)
may be due to inspiratory/diaphragm muscle fiber injury/
fatigue since IRL was performed until task failure, which
occurred after 54  10 min. However, inspiratory muscle
fatigue was assessed using a volitional measure of MIP, which
may decline following IRL until task failure due to a decrease
in central drive globally rather than diaphragm fatigue (2, 44).
The question of whether respiratory muscles release IL-6
during exercise and if this is related to diaphragm fatigue may
be better addressed using volitional hyperpnea at rest. In this
model, validity is improved by mimicking the breathing and
respiratory muscle recruitment patterns experienced during
whole body exercise (4, 36). The presence of diaphragm
fatigue can also be measured more objectively by using bilat-
eral phrenic nerve stimulation (2).
Recent evidence suggests that the plasma IL-6 response to
exercise is attenuated following whole body resistance (30) and
endurance (1, 16, 70) training. Increases in basal levels of IL-6
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receptor  (1, 34) or an increase in antioxidant enzymes (70)
may explain such reductions. Alternatively, a strong stimulus
for IL-6 production by skeletal muscle fibers is muscle glyco-
gen depletion (34, 56), which is attenuated in trained muscle
(16, 22) secondary to training-induced increases in mitochon-
drial density (27). Inspiratory muscle training (IMT) may elicit
similar morphological adaptations in the inspiratory muscles
(7–9, 51) and thus also attenuate the plasma IL-6 response to
whole body exercise and/or volitional hyperpnea.
Therefore the aim of this study was to examine whether the
respiratory muscles contribute to exercise-induced increases in
plasma IL-6 concentration, if this is related to diaphragm
fatigue, and whether IMT attenuates the plasma IL-6 response
to whole body exercise and/or a volitional mimic of the
exercise hyperpnea.
METHODS
Participants. Twelve nonsmoking recreationally active males pro-
vided written, informed consent to participate in the study, which was
approved by the local ethics committee. A self-reporting medical
questionnaire confirmed that participants were free from illness and
injury and not taking any medication and/or antioxidant supplements
during the study. Each participant completed a 24-h diet record prior
to their first trial, which was then replicated prior to all subsequent
trials. Throughout the study, participants were instructed to adhere to
their habitual training regimen and not to engage in any strenuous
exercise the day preceding and the day of a trial. Participants arrived
at the laboratory 4 h postprandially, having abstained from alcohol
and caffeine in the 24 h before testing.
Experimental design. Participants attended the laboratory on six
separate occasions, before and after a 6-wk intervention (Fig. 1). Each
laboratory visit was separated by 48 h and took place at the same time
of day. During the first visit, participants were familiarized with all
testing procedures and pulmonary function and MIP were measured.
During the second visit participants performed a cycling lactate
minimum test to estimate maximal lactate steady state power.
The subsequent three experimental trials lasted 1 h and comprised
1) passive rest (PASSIVE), 2) cycling exercise at the participants
lactate minimum power (EX), and 3) volitional hyperpnea at rest
whereby participants mimicked the breathing and respiratory muscle
recruitment patterns achieved during EX (HYPEX). Since EX had to
precede HYPEX, the experimental trials were only partially random-
ized. Following the final trial, participants were randomly, and
equally, divided into an IMT or placebo (PLA) group and completed
the intervention. At least 48 h postintervention, participants repeated
the lactate minimum test and experimental trials in the same order as
preintervention. All trials were performed on an electromagnetically
braked cycle ergometer (Excalibur Sport; Lode, Groningen, Nether-
lands).
Pulmonary function and maximal inspiratory mouth pressure.
Pulmonary function was assessed according to published guidelines
(46) using a pneumotachograph (Pneumotrac; Vitalograph, Bucking-
hamshire, UK) calibrated with a 3-liter syringe. A hand-held mouth
pressure meter (MicroRPM; CareFusion, Hampshire, UK) measured
MIP as an index of global inspiratory muscle strength. The mouth-
piece assembly incorporated a 1 mm orifice to prevent glottic closure
during inspiratory efforts. Maneuvers were performed while standing,
initiated from residual volume, and sustained for at least 1 s. Repeat
efforts separated by 30 s were performed until three serial measures
differed by no more than 10% or 10 cmH2O, whichever was smallest
(7, 8, 31). The highest value recorded was used for subsequent
analysis.
Lactate minimum test. The lactate minimum test was performed
following the procedures of Johnson et al. (32) who reported excellent
agreement between lactate minimum and maximal lactate steady-state
cycling powers (mean bias  95% limits of agreement: 2  22 W).
The test comprised three consecutive phases: 1) blood lactate concen-
tration ([La]B) elevation phase comprising maximal incremental
exercise, 2) 8 min recovery phase at 60 W, and 3) incremental phase
comprising five consecutive 4-min exercise stages at intensities of 45,
50, 55, 60, and 65% of the maximum power achieved during the
lactate elevation phase. During the [La]B elevation phase, power
output was increased by 10 W every 15 s to elicit exercise intolerance
in 10 min. The highest oxygen uptake recorded in any 30 s period
defined peak oxygen uptake (V˙ O2peak). During the incremental phase,
blood samples were taken in the final seconds of each stage, and the
lactate minimum power (i.e., estimated maximal lactate steady state
power) was calculated as the nadir of a second-order polynomial
fitting the [La]B against power data.
Experimental trials. During experimental trials the configuration of
the cycle ergometer and the body position adopted by each participant
were identical to those adopted during the lactate minimum test. Each
trial was preceded by a 5-min rest period, and during PASSIVE
participants remained seated on the cycle ergometer for the duration
Fig. 1. Schematic of experimental design.
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of the trial. During pre- and postintervention EX trials participants
cycled at their preintervention lactate minimum power and each
participant adopted the same cycling cadence during all trials. During
HYPEX participants mimicked the breathing (tidal volume, VT;
breathing frequency, fB; and duty cycle, TI/TTOT) and respiratory
muscle recruitment (peak transdiaphragmatic pressure, Pdipeak) pat-
terns attained during preintervention EX. These variables were en-
semble averaged into six 10-min blocks from the EX data and targets
were updated during the HYPEX trial. During the postintervention
HYPEX trial, participants mimicked the breathing and respiratory
muscle recruitment patterns performed during the preintervention
HYPEX trial. An audio metronome paced fB and TI/TTOT, and
real-time visual feedback of VT and Pdipeak was provided throughout.
The use of Pdipeak targets allowed us to more precisely control the
mechanical work of breathing during volitional hyperpnea (4, 36). All
experimental trials were performed in an environmental chamber (Design
Environmental WIR52–20HS; Design Environmental, Gwent, UK) at
20°C and 90% relative humidity to minimize mucosal drying during
HYPEX.
Flow, pulmonary gas exchange, and pressure measurements. Dur-
ing all trials, participants wore a facemask (model 7940; Hans Ru-
dolph) connected to a pneumotachograph and ventilatory and pulmo-
nary gas exchange responses were measured breath by breath (ZAN
600USB; Nspire Health, Oberthulba, Germany). During experimental
trials a two-way nonrebreathing valve (model 2730; Hans Rudolph)
was attached distally to the pneumotachograph and a 1.5 m length of
wide-bore tubing was connected to the inspiratory port. During
HYPEX, CO2 was added into this tubing to increase FICO2 and thus
retain end-tidal and, consequently, blood PCO2 at levels commensurate
with rest (9, 33). On the expiratory port of the two-way valve a Fleisch
no. 3 pneumotachograph was attached and connected to a differential
pressure transducer ( 2.5 cmH2O) (TSD160A; BIOPAC Systems)
and differential bridge amplifier (DA100C; BIOPAC Systems) to
allow alignment of flow and pressure signals. Esophageal (Pe) and
gastric (Pg) pressures were measured using two thin-walled (0.6
mm) latex balloons sealed over a single polyethylene catheter (Nspire
Health), which was attached to a differential pressure transducer (
400 cmH2O) (TSD104A; BIOPAC Systems) and differential bridge
amplifier (DA100C; BIOPAC Systems). Pressure transducers were
calibrated across the physiological range and pressure and flow (from
the Fleisch pneumotachograph) signals were sampled at 200 Hz using
an analog-digital converter and recorded using specific data acquisi-
tion software (Acqknowledge version 3.7.3; BIOPAC systems). The
balloon catheter was initially positioned in the stomach following
local anesthesia of the nasal mucosa and posterior pharynx using 2%
lidocaine (Instillagel; Farco-Pharma, Cologne, Germany). Following a
Valsalva maneuver, the esophageal and gastric balloons were evacu-
ated of air using a glass syringe and subsequently filled with 1 and 2
ml of air, respectively. The catheter was then withdrawn until, during
repeated sniffs, Pe became negative. Subsequently, the catheter was
withdrawn a further 10 cm. During the first experimental trial the
distance from the tip of the nares to the most distal point of the
catheter was recorded and replicated in subsequent trials. Transdia-
phragmatic pressure (Pdi) was calculated by subtracting Pe from Pg.
Pdi and Pe were integrated over the period of inspiratory flow and
multiplied by fB and labeled the diaphragm pressure-time product
(PTPdi) and the inspiratory muscle pressure-time product (PTPe),
respectively. Nonphysiological flows and pressures that resulted from
swallowing, coughing, and breath holding were identified by visual
inspection and removed. Breathing mechanics data were ensemble
averaged into six 10-min blocks and used for subsequent analysis.
Bilateral anterior magnetic phrenic nerve stimulation. Bilateral
anterior magnetic phrenic nerve stimulation (BAMPS) (47) was ap-
plied using two double 25 mm coils connected to two Magstim 2002
stimulators (Magstim, Dyfed, UK) that were triggered simultaneously.
Participants initially rested for 20 min to minimize postactivation
potentiation (41, 69). The location of each phrenic nerve was then
identified by stimulating the area at the posterior border of the
sternomastoid muscle at the level of the cricoid cartilage and deter-
mining the area associated with the largest peak to peak amplitude of
transdiaphragmatic twitch pressure (Pditw). This location was marked
with indelible ink and used for subsequent stimulations. During
stimulations, participants were seated upright with no abdominal
binding (37, 42), wore a noseclip, and prior to stimulation were
instructed to hold at functional residual capacity (28, 55), which was
inferred from visual feedback of Pe.
Skin surface electromyography (EMG) of the right costal dia-
phragm was recorded using bipolar surface electrodes (self-adhesive,
Ag-AgCl, 10 mm recording surface diameter; Unilect, Worcester-
shire, UK) placed on the sixth and eighth intercostal spaces in the
anterior axillary line (24). Electrodes were positioned to optimize peak to
peak amplitude of M-wave responses. EMG signals were passed through
a differential amplifier (1902 Mk IV; Cambridge Electronic Design,
Cambridge, UK), sampled at 2,000 Hz using an analog-digital converter
(Micro 1401; Cambridge Electronic Design) and recorded using specific
data acquisition software (Spike 2 version 5.12; Cambridge Electronic
Design).
To determine supramaximal phrenic nerve stimulation, three single
twitches were obtained every 30 s at intensities of 50, 60, 70, 80, 85,
90, 95, and 100% of maximal stimulator output. A plateau in Pditw and
M-wave responses with increasing stimulation intensities indicated
maximum depolarization of the phrenic nerves. The technical consid-
erations regarding supramaximal stimulation have been described
previously (17, 59). Pditw was assessed every 30 s using eight single
stimuli at 100% of maximal stimulator output. Pditw was measured at
baseline and within 15 (15 min), 35 (35 min), and 60 (60 min)
min after each experimental trial. Additionally, Pditw at each measure-
ment point was followed by the assessment of the potentiated Pditw
response. Participants performed a 3-s maximal Müeller maneuver
and 5 s later a single stimuli was delivered. This procedure was
repeated six times with each measure separated by 30 s. A potentiated
Pditw has greater sensitivity to fatigue especially when the degree of
fatigue is small (39, 40). The average of the median three individual
Pditw responses were used for analysis. Diaphragm fatigue was defined
as a 15% reduction in Pditw compared with the baseline value (38).
Blood analyses and additional measurements. Arterialized venous
blood was sampled from a dorsal hand vein via an indwelling 21-G
cannula (45). Arterialization was ensured by immersing the hand in
water at 40°C for 10 min prior to cannulation and by warming the
hand during trials using an infrared lamp. During the experimental
trials blood samples were taken at rest, every 3 min for the initial 15
min, and every 5 min thereafter, and analyzed immediately for PCO2
and pH (ABL520; Radiometer, Copenhagen, Denmark), which were
corrected for changes in rectal temperature (Squirrel 2020; Grant
Instruments, Cambridge, UK). At rest and every 10 min during each
trial [La]B was determined using an automated analyzer (Biosen
C_line Sport; EKF Diagnostics, Barleben, Germany), and measure-
ments were taken for cardiac frequency (fC) using short-range telem-
etry (Polar S610; Polar, Kempele, Finland), estimated arterial oxygen
saturation (SpO2) using infrared fingertip pulse oximetry (Model
8600; Nonin), and rating of perceived exertion (RPE) for dyspnea and
leg discomfort using Borg’s modified CR10 scale (6). At rest, imme-
diately after (0 h) and 1 (1 h), 2 (2 h), and 24 (24 h) h after each
experimental trial, 5 ml blood samples were taken for the measure-
ment of plasma IL-6 concentration. Blood was transferred into pre-
cooled tubes containing 1.6 mg/ml of K3E EDTA (SARSTEDT,
Leicester, UK) and immediately centrifuged for 15 min at 1,000 	 g
and 5°C. The plasma supernatant was subsequently removed and
stored at 80°C until further analysis. Plasma IL-6 concentrations
were measured in duplicate using a commercial solid phase sandwich
ELISA (Quantikine HS; R&D Systems, Abingdon, UK). The assay
has a detection limit of 0.039 pg/ml. To minimize the effect of
interassay variation, pre- and postintervention samples from both
groups were measured during the same assay. The inter- and intra-
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assay coefficient of variation (CV) for plasma IL-6 concentration
was 10%.
Inspiratory muscle training and placebo interventions. The inter-
vention lasted 6 wk. The IMT group performed 30 consecutive
dynamic inspiratory efforts twice daily using an inspiratory pressure-
threshold device (POWERbreathe Classic series 1st generation; Ga-
iam, UK). The initial training load was 50% MIP. Thereafter, partic-
ipants periodically increased the load so that 30 maneuvers could only
just be completed. Each inspiratory effort was initiated from residual
volume and participants strove to maximize VT. This regimen is
known to be effective in eliciting an adaptive response (7–9, 52). The
PLA group inhaled one puff twice daily from a sham metered dose
inhaler (Vitalograph). The inhaler contained compressed air only but
was promoted to the participants as delivering a novel drug that
reduces breathing-induced inflammation. During the postintervention
period the IMT and PLA groups performed their intervention 2
days/wk, which is sufficient to maintain improvements in inspiratory
muscle function following IMT (52). These maintenance sessions
were performed 48 h before and 48 h after experimental trials. All
participants completed a training diary throughout the study to record
adherence to the prescribed intervention and whole body training
sessions.
Statistical analyses. Statistical analyses were performed using
SPSS for Windows (IBM, Chicago, IL). Between- and within-group
comparisons of baseline characteristics, including pulmonary function
and MIP, were made using independent and paired t-tests, respec-
tively. A three-way ANOVA was used to analyze the effects of
“intervention” (pre- vs. post-“treatment”) and “time” (10, 20, 30, 40,
50, and 60 min for all physiological and perceptual variables; 0, 1,
2, and24 h for plasma IL-6 data; or baseline,15,35, and60
min for Pditw data) with a between-subject factor of “trial” (EX vs.
HYPEX) for breathing and respiratory muscle recruitment pattern
data, or “treatment” (IMT vs. PLA) for all other data. Intervention 	
treatment interaction effects and within-group changes were further
explored by analyzing IMT and PLA groups separately using
two-way repeated measures ANOVA. Reliability was assessed
using a CV calculated from a pooled mean of both groups and all
trials. Statistical significance was set at P  0.05. Results are
presented as means  SD.
RESULTS
Age (IMT vs. PLA: 27  7 vs. 22  3 yr), body mass
(80  6 vs. 74  7 kg), height (181  5 vs. 177  4 cm), and
V˙ O2peak (52  6.2 vs. 47  5.7 ml·kg1·min1) were not
different between groups. Maximum power (378  22 vs.
336  23 W) and lactate minimum power (199  8 vs. 170 
19 W) were higher (P 0.01) in the IMT group compared with
the PLA group. All other preintervention measurements were
not different between groups. V˙ O2peak, maximum power, and
lactate minimum power were unchanged after both IMT and
PLA. In both groups all responses remained unchanged
throughout PASSIVE trials (data not shown).
Pulmonary function and maximal inspiratory pressure. Pre-
intervention pulmonary function (data not shown) and MIP
were within normal limits. Compliance with the intervention
was excellent in both IMT and PLA groups with 96  1 and
93  1% of sessions completed, respectively. Pulmonary
function was unchanged in both groups postintervention,
whereas MIP increased from 168  49 to 202  39 cmH2O
(24  16%) after IMT (P  0.01). Inspection of training
diaries revealed habitual whole-body training remained con-
stant in both groups.
Breathing and respiratory muscle recruitment patterns.
When performed separately for IMT and PLA groups, three-
way ANOVA with repeated measures across intervention (pre-
vs. posttreatment) and time (10, 20, 30, 40, 50, and 60 min),
with a between-subject factor of trial (EX vs. HYPEX), re-
vealed no main effects of intervention or trial for breathing and
Table 1. Physiological and perceptual responses to EX and HYPEX trials for IMT and PLA groups
EX HYPEX
Preintervention Postintervention Preintervention Postintervention
IMT
V˙ E, l/min 81.0  13.0 75.1  6.1 77.3  15.1 77.0  15.9
VT, liters 2.41  0.53 2.40  0.53 2.31  0.53 2.31  0.53
fB, breaths/min 36  9 33  6 35  9 35  9
TI/TTOT 0.47  0.01 0.48  0.02 0.49  0.04 0.48  0.05
[La]B, mmol/l 4.21  1.88 2.74  1.08 0.84  0.14 0.92  0.10
pH 7.357  0.031 7.376  0.020 7.414  0.025 7.424  0.022
PCO2, mmHg 41.8  3.5 41.4  3.1 41.9  3.8 40.9  2.4
fC, beats/min 163  15 159  14 68  9 68  12
SpO2, % 95  1 95  1 99  1 99  1
RPE (dyspnea) 3.9  1.7 2.0  1.5 2.8  1.6 1.7  1.3
RPE (leg) 5.8  1.3 5.2  1.2 0.0  0.0 0.0  0.0
PLA
V˙ E, liters/min 61.6  14.5 59.6  12.5 58.2  13.4 59.1  14.6
VT, liters 1.77  0.34 1.78  0.27 1.69  0.36 1.72  0.40
fB, breaths/min 36  7 35  7 35  7 35  7
TI/TTOT 0.48  0.01 0.48  0.02 0.49  0.03 0.49  0.02
[La]B, mmol/l 4.20  1.19 4.00  1.13 0.98  0.18 0.93  0.39
pH 7.358  0.017 7.359  0.022 7.400  0.03 7.395  0.03
PCO2, mmHg 41.2  2.7 41.1  2.6 42.1  2.8 42.5  3.2
fC, beats/min 158  16 153  14 66  10 63  7
SpO2, % 96  1 96  1 99  1 99  1
RPE (dyspnea) 3.7  2.9 3.2  4.4 1.6  2.1 1.3  1.7
RPE (leg) 5.1  2.7 5.2  3.4 0.0  0.0 0.0  0.0
Values are mean  SD. V˙ E, minute ventilation; VT, tidal volume; fB, breathing frequency; TI/TTOT, duty cycle; [La]B, blood lactate concentration; PCO2,
partial pressure of carbon dioxide; fC, cardiac frequency; SpO2, arterial oxygen saturation; RPE, rating of perceived exertion. See text for description of analyses.
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respiratory muscle recruitment patterns. This shows that the
breathing and respiratory muscle recruitment patterns observed
during EX were successfully mimicked in HYPEX and that
these factors were the same before and after IMT and PLA
(Table 1 and Figs. 2 and 3). The only exception was that in
the IMT group PTPdi/PTPe changed differently over time
between the two trials (trial 	 time interaction, P  0.008)
and in the PLA group PTPdi changed differently over time
between the two trials (trial 	 time interaction, P  0.026)
(Table 1 and Figs. 2 and 3). The intertrial CV for Pdipeak at
rest was 7%.
Plasma interleukin-6 concentration. For EX trial plasma
IL-6 concentration data, three-way ANOVA with repeated
measures across intervention (pre- vs. posttreatment) and time
(0, 1, 2, and 24 h), with a between-subject factor of
treatment (IMT vs. PLA), revealed a main effect of time (P 
0.01) and intervention (P  0.013) and a trend for an inter-
vention 	 treatment interaction (P  0.093) (Fig. 4). To
explore the nature of this interaction subsequent, two-way
ANOVA with repeated measures across time (0, 1, 2, and
24 h) and intervention (pre- vs. posttreatment) were per-
formed separately for IMT and PLA groups and revealed that
plasma IL-6 concentration was reduced after IMT (main effect
of intervention, P  0.039), whereas there was no change after
PLA (P  0.272). For HYPEX trial plasma IL-6 concentration
data, three-way ANOVA revealed a main effect of time (P 
Fig. 2. Peak transdiaphragmatic pressure (Pdipeak; A),
diaphragm pressure-time product (PTPdi; B), inspiratory
muscle pressure-time product (PTPe; C), and the rela-
tive contribution of diaphragm to the inspiratory muscle
pressure-time product (PTPdi/PTPe; D) for the IMT
group. Values are means  SD.
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0.01), but not for intervention (P  0.306), and no interven-
tion 	 treatment interaction (P  0.304) (Fig. 4).
Blood lactate concentration, pH, and PCO2. For EX trial
data, three-way ANOVA with repeated measures across inter-
vention (pre- vs. posttreatment) and time (10, 20, 30, 40, 50,
and 60 min), with a between-subject factor of treatment (PLA
vs. IMT), revealed intervention 	 treatment interactions for
[La]B (P  0.016) and pH (P  0.050) (Table 1). To explore
the nature of these interactions, subsequent two-way ANOVA
with repeated measures across time (10, 20, 30, 40, 50, and 60
min) and intervention (pre- vs. posttreatment) were performed
separately for IMT and PLA groups. After IMT, [La]B was
reduced and pH was higher (main effects of intervention, P 
0.01), whereas [La]B and pH were unchanged after PLA.
PCO2 during EX was unchanged postintervention (Table 1).
During the preintervention HYPEX trial resting [La]B was
0.57  0.11 and 0.76  0.12 mmol/l in IMT and PLA groups,
respectively. A three-way ANOVA revealed that [La]B in-
creased (main effect of time, P  0.042) and responses were
unchanged postintervention (Table 1). There was no main
effect of time for pH and PCO2 showing that these variables
were maintained at rest during HYPEX (Table 1).
Twitch transdiaphragmatic pressures. A plateau (i.e., no
significant increase in amplitude with increasing stimulation
intensity) in Pditw and M-wave amplitude (data not shown) was
observed in response to supramaximal BAMPS, indicating
Fig. 3. Peak transdiaphragmatic pressure (Pdipeak; A),
diaphragm pressure-time product (PTPdi; B), inspiratory
muscle pressure-time product (PTPe; C), and the rela-
tive contribution of diaphragm to the inspiratory muscle
pressure-time product (PTPdi/PTPe; D) for the PLA
group. Values are means  SD.
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maximal depolarization of the phrenic nerves. Preintervention
Pditw and potentiated Pditw for the IMT group were 15.6  5.1
and 23.3 8.6 cmH2O at baseline during EX and the inter- and
intratrial CV for baseline Pditw and potentiated Pditw was 8%.
Three-way ANOVA with repeated measures across interven-
tion (pre- vs. posttreatment) and time (baseline,15,35, and
60 min), with a between-subject factor of treatment (PLA vs.
IMT), revealed no main or interaction effects for Pditw and
potentiated Pditw in either EX or HYPEX. Therefore there was
no evidence of diaphragm fatigue following any trial.
Perceptual responses, cardiac frequency, and arterial oxy-
gen saturation. For EX trial data, three-way ANOVA with
repeated measures across intervention (pre- vs. posttreatment)
and time (10, 20, 30, 40, 50, and 60 min), with a between-
subject factor of treatment (PLA vs. IMT), revealed a main
effect of intervention (P  0.010) and an intervention 	
time 	 treatment interaction (P  0.012) for RPE (dyspnea)
(Table 1). To explore the nature of these findings, subsequent
two-way ANOVA with repeated measures across time (10, 20,
30, 40, 50, and 60 min) and intervention (pre- vs. posttreat-
ment) were performed separately for IMT and PLA groups.
RPE (dyspnea) was lower after IMT (main effects of interven-
tion P  0.006) but unchanged after PLA. For HYPEX trial
data, three-way ANOVA revealed an intervention 	 treatment
interaction (P  0.024) for RPE (dyspnea) (Table 1). To
explore the nature of this interaction, subsequent two-way
ANOVA performed separately for IMT and PLA groups re-
vealed a trend for RPE (dyspnea) to be lower after IMT (main
effect of intervention, P  0.054) but not after PLA. Three-
way ANOVA revealed no main or interaction effects for RPE
(leg), fC, or SpO2 in EX or HYPEX trials (Table 1).
DISCUSSION
Main findings. The main findings of this study were that
plasma IL-6 concentration increased following strenuous
whole-body exercise (EX) and a volitional mimic of the breath-
ing and respiratory muscle recruitment patterns achieved dur-
ing EX (HYPEX) and that these increases occurred in the
absence of diaphragm fatigue. In addition, the plasma IL-6
response to EX was attenuated following IMT.
To our knowledge, we are the first to report an increase in
plasma IL-6 concentration following a volitional mimic of the
exercise hyperpnea. The increase in IL-6 following HYPEX
was of a similar magnitude to that reported following IRL at
75% MIP until task failure (64). However, our experimental
model provides a more ecologically valid approach to assess
whether the respiratory muscles release IL-6 during whole-
body exercise. We are also confident that the increase in
plasma IL-6 concentration observed during HYPEX is not an
artifact of the experimental conditions since plasma IL-6 con-
centration was unchanged during the PASSIVE trial. Our data
therefore suggest that the respiratory muscles do indeed con-
tribute to the increase in plasma IL-6 concentration during
whole body exercise.
Stimuli for interleukin-6. The stimuli responsible for the
increase in plasma IL-6 concentration following HYPEX could
not be established from the present study. We found no
evidence of diaphragm fatigue following HYPEX, and confi-
dence in our data is supported by the demonstration of supra-
maximal stimulation in Pditw and M-wave responses and ex-
cellent inter-/intratrial reliability in Pditw. Therefore our data do
not support the notion (63, 64) that diaphragm fatigue triggers
IL-6 release.
Oxidative stress due to enhanced generation of ROS and
nitrogen species is an important regulator of IL-6 production.
ROS can upregulate IL-6 in the diaphragms of rats exposed to
IRL (54) and antioxidants can attenuate the plasma IL-6
response to IRL in humans (63). ROS are also upregulated by
respiratory acidosis (3); however, we were careful to maintain
PCO2 at resting levels. Upstream of ROS, nitric oxide produc-
tion may be involved in the transcriptional signaling of IL-6
(57) and has been shown to regulate IL-6 production within the
diaphragm of rats exposed to IRL (53). However, since muscle
glycogen depletion during prolonged and strenuous lower-
Fig. 4. Plasma interleukin-6 (IL-6) concentration for
EX (bottom) and HYPEX (top) trials. Values are
means  SD.
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body exercise is a strong stimulus for enhanced IL-6 produc-
tion by skeletal muscle fibers (34, 56), a more likely mecha-
nism for the production of IL-6 may be a reduction in respi-
ratory muscle glycogen content. This notion is supported by
the reduced diaphragm glycogen content of murines exposed to
IRL (13) and whole-body exercise (25, 29).
Source of plasma interleukin-6. Contracting skeletal muscle
accounts for most (but not all) of the increase in plasma IL-6
concentration observed during whole body exercise (58). Thus,
although our experimental model did not allow the source(s) of
the increased plasma IL-6 during HYPEX to be established, we
attribute this increase to, primarily, increased IL-6 release from
contracting respiratory muscles. This notion is consistent with
the increased IL-6 mRNA and protein expression in the dia-
phragm of rats exposed to IRL (53, 54, 62), and the higher IL-6
protein expression in the external intercostals of COPD pa-
tients compared with healthy controls (12).
However, there may have been additional contributions from
other sources to the increase in plasma IL-6 concentration
during HYPEX. Excessive expiratory muscle contractions dur-
ing HYPEX (as evidenced by a higher PTPdi), which has been
previously observed in humans mimicking the pressure/flow
characteristics of exercise hyperpnea (36), may have resulted
in greater IL-6 release from expiratory muscles. The brain was
also shown to release small amounts of IL-6 (60 pg/min)
following 60 min of cycling exercise (49). Furthermore, IL-6
may be upregulated within the lungs and subsequently enter the
systemic circulation from permeation of epithelial and endo-
thelial barriers with increased transmural pressures (61). This
has been observed in murines exposed to negative or positive
pressure ventilated hyperventilation (65) or IRL (60). How-
ever, this causes profound overdistension of the lung, which is
unlikely during spontaneous hyperpnea in humans due to
self-regulation of end-inspiratory and/or end-expiratory lung
volumes.
When expressed relative to the size of the muscle group
used, the arm muscles release greater amounts of IL-6 than leg
muscles, and this is not directly related to release or uptake of
exogenous substrate or muscle glycogen utilization (26). It
may be possible that the respiratory muscles also contribute
differently to systemic IL-6 release than other skeletal muscles
due to differences in fiber type composition and vascular
supply (48).
Effects of inspiratory muscle training on plasma interleu-
kin-6 concentration. The present study is the first to demon-
strate an attenuated plasma IL-6 response to whole-body ex-
ercise following IMT. Reduced IL-6 production by inspiratory
muscles following IMT may result from increases in basal
levels of IL-6 receptor  (1, 34) or antioxidant enzymes (70) or
a reduction in muscle glycogen utilization (16, 22) secondary
to training-induced increases in mitochondrial density (27).
However, the decrease in plasma IL-6 concentration during EX
is unlikely to be explained by these changes alone as 1) plasma
IL-6 concentration during HYPEX was not reduced and 2) the
reduction in plasma IL-6 concentration during EX following
IMT was greater than the increase observed during HYPEX.
Thus alternate explanations may exist. First, when isolated
diaphragmatic fibers are incubated with CO2 there is an in-
crease in ROS (3). If ROS are a stimuli for IL-6 production, the
increase in pH during EX (which did not occur in HYPEX)
may have downregulated IL-6 production within the leg and/or
respiratory muscles. Second, while supporting empirical evi-
dence is not strong, respiratory muscle metaboreflex activation
may be attenuated by IMT (66), thus promoting increased
blood flow to the liver (21) and/or leg muscles (43). Increased
blood flow to the liver may increase hepatosplanchnic uptake
of IL-6 (21), whereas increased leg blood flow may result in
less muscle glycogen utilization due to increased oxygen (5)
and/or glucose (19) delivery.
Application to asthma and COPD. Asthma attacks and
COPD exacerbations lead to systemic inflammation due to
inflammatory cytokines. The local source of these cytokines is
not, however, fully understood. Some suggest that cytokines
spill out from the lungs into the systemic circulation, whereas
others suggest that multiple organs contribute (35, 68). Con-
sistent with previous studies (11, 63, 64), our data suggest that
the respiratory muscles directly contribute to the systemic
inflammation observed in these patients when the work of
breathing is increased. Furthermore, based on the findings of
the present study, it is attractive to speculate that IMT may
reduce the plasma IL-6 response during a period of increased
respiratory muscle work in asthma and COPD patients.
Conclusion. In conclusion, plasma IL-6 concentration was
increased, in the absence of diaphragm fatigue, following
strenuous whole-body exercise (EX) and a volitional mimic of
the exercise hyperpnea (HYPEX). Furthermore, the plasma
IL-6 response to EX was attenuated following IMT. That the
respiratory muscles may contribute to the increase in plasma
IL-6 during whole body exercise raises several key questions:
what other inflammatory cytokines are released from respira-
tory muscles during exercise and what are the key regulators of
this IL-6 release? Are other cytokines increased/decreased
following IMT and does this create a pro- or antiinflammatory
response during exercise or volitional hyperpnea? What is the
effect of IMT on the systemic inflammation observed in asthma
and COPD patients?
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